OREANDA-NEWS. Pharmstandard OJSC (LSE: PHST IL, RTS: PHST RU) (further “Pharmstandard” or the “Company” announces the completion of the transaction to acquire a 100% share capital in Bever Pharmaceutical Pte Ltd (Singapore) (“Bever”) (the “Transaction”).

The amount of the transaction is USD 590million. The Transaction will be funded by the combination of Pharmstandard's shares and GDRs owned by Pharmstandard-Leksredstva OJSC in the amount of USD 542 million (price per share of RUB 2,235.4 and price per GDR of USD 20.76) and cash of USD 48 million, which may be financed from external sources. Pharmstandard-Leksredstva OJSC currently holds Pharmstand-ard's shares and GDRs on its balance sheet at approximately USD 475 million.

All settlements will be finalized by the end of December 2013.

The Company's strategic rationale for the Transaction includes securing a long-term fixed-cost supply of critical active pharmaceutical ingredients for two flagship OTC brands Arbidol® and Aphobazolum® as well as significantly increasing the Company's profitability.

It is expected that Bever will be included in a proposed spin-off of the Company's branded over-the-counter business.

Bever is now a part of Pharmstandard Group and will be included into Company's perimeter of operations in the near term.